Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autobio Diagnostics CoSHSE:603658 -2.18%95 Net Margin % is 24.46% as of Jun. 2026, which is 10% below its 10-year median of 27.06. GuruFocus rates SHSE:603658 with a GF Score™ of 95/100 and a GF Value™ of ¥40.43 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Autobio Diagnostics Co ranks better than 92.02% on this metric.
The historical rank and industry rank for Autobio Diagnostics Co's Net Margin % or its related term are showing as below:
SHSE:603658'
s Net Margin % Range Over the Past 10 Years
Min: 23.54 Med: 27.06 Max: 35.68
Current: 23.54
SHSE:603658's Net Margin % is ranked better than 92.02% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 2.24
vs SHSE:603658: 23.54
Autobio Diagnostics Co (SHSE:603658) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Autobio Diagnostics Co Net Margin % Related Terms
Autobio Diagnostics Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603658 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Autobio Diagnostics Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autobio Diagnostics Co Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autobio Diagnostics Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where Autobio Diagnostics Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autobio Diagnostics Co (SHSE:603658) has a Net Margin % of 24.46% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Autobio Diagnostics Co and its competitors. This is 10% below median its historical median of 27.06. Over the past decade, Autobio Diagnostics Co's Net Margin % has ranged from 23.54 to 35.68. According to the industry distribution chart, Autobio Diagnostics Co ranks #65 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 8%.
Is Autobio Diagnostics Co's Net Margin % too high?
Autobio Diagnostics Co's current Net Margin % of 24.46% is 10% below median its 10-year median of 27.06. Over the past 10 years, this metric has ranged from a low of 23.54 to a high of 35.68. The Medical Devices & Instruments industry median Net Margin % is 2.24. Autobio Diagnostics Co's value of 24.46% is 992% above this industry median. Based on the distribution chart, Autobio Diagnostics Co ranks #65 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autobio Diagnostics Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Autobio Diagnostics Co's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Autobio Diagnostics Co ranks #65 out of 815 companies for Net Margin %. This places Autobio Diagnostics Co in the top 8% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.24. Autobio Diagnostics Co's value of 24.46% is 992% above this benchmark. Historically, Autobio Diagnostics Co's own Net Margin % has ranged from 23.54 to 35.68 over the past decade. While the company's 10-year median is 27.06 vs. the industry median of 2.24, Autobio Diagnostics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.24, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autobio Diagnostics Co's current Net Margin % of 24.46% is 992% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Autobio Diagnostics Co and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autobio Diagnostics Co's current Net Margin % is 24.46%, which is 10% below median its own 10-year median of 27.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autobio Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Autobio Diagnostics Co (SHSE:603658) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥40.43, compared to a current price of ¥32.68 — trading 19.2% below its estimated fair value. The current Net Margin % is 24.46%, which is 10% below median its 10-year median of 27.06 and 992% above the Medical Devices & Instruments industry median of 2.24. Autobio Diagnostics Co's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Autobio Diagnostics Co (SHSE:603658), the current Net Margin % is 24.46% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autobio Diagnostics Co (SHSE:603658) Overvalued in 2026?
Based on GuruFocus' analysis, Autobio Diagnostics Co stock appears to be undervalued.
The current stock price of ¥32.68 is trading 19.2% below its estimated GF Value™ of ¥40.43.
GuruFocus considers Autobio Diagnostics Co to be Modestly Undervalued.
Key valuation signals for SHSE:603658:
Net Margin %: 24.46% (10% below median its 10-year median of 27.06)
GF Value™: ¥40.43 vs. price of ¥32.68 (19.2% below fair value)
Industry Position: 992% above the Medical Devices & Instruments median (#65 of 815)
No single metric tells the full story. See the SHSE:603658 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autobio Diagnostics Co Ltd is a clinical diagnostics company in China. It specializes in research and development, production, and sales of in vitro diagnostic reagents and instruments. The company's main products include immunoassay, microbiological, molecular diagnostic, and biochemical reagents, along with immunoassay, microbiological, molecular detection, and mass spectrometry instruments, as well as auxiliary testing devices.
95GF Score
Get the complete analysis for SHSE:603658
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603658 has been successfully added to your 
